DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $454,129,528 | -8.2% | 2,065,038 | +0.2% | 0.37% | -3.1% |
| Q2 2023 | $494,531,760 | -14.9% | 2,060,549 | -10.6% | 0.38% | -11.1% |
| Q1 2023 | $581,083,765 | -6.7% | 2,305,522 | -1.7% | 0.43% | -12.2% |
| Q4 2022 | $622,821,832 | +2.3% | 2,346,552 | -0.5% | 0.49% | -1.4% |
| Q3 2022 | $609,103,000 | +3.7% | 2,358,214 | +1.8% | 0.50% | +10.6% |
| Q2 2022 | $587,290,000 | +0.9% | 2,316,544 | +16.8% | 0.45% | +16.8% |
| Q1 2022 | $581,764,000 | -14.0% | 1,983,308 | -3.6% | 0.39% | -5.8% |
| Q4 2021 | $676,571,000 | +5.5% | 2,056,385 | -2.4% | 0.41% | +3.0% |
| Q3 2021 | $641,202,000 | +9.2% | 2,106,168 | -3.7% | 0.40% | +15.0% |
| Q2 2021 | $587,100,000 | +12.0% | 2,187,732 | -6.0% | 0.35% | +6.1% |
| Q1 2021 | $524,015,000 | -9.4% | 2,328,126 | -10.6% | 0.33% | -12.6% |
| Q4 2020 | $578,651,000 | +1.1% | 2,604,892 | -2.0% | 0.37% | -3.1% |
| Q3 2020 | $572,460,000 | +9.4% | 2,658,525 | -10.2% | 0.39% | +4.3% |
| Q2 2020 | $523,479,000 | +31.1% | 2,960,353 | +2.6% | 0.37% | +7.9% |
| Q1 2020 | $399,319,000 | -11.8% | 2,885,045 | -2.2% | 0.34% | -3.7% |
| Q4 2019 | $452,528,000 | +6.3% | 2,948,452 | +0.0% | 0.36% | -3.8% |
| Q3 2019 | $425,660,000 | +5.7% | 2,947,171 | +4.6% | 0.37% | +3.1% |
| Q2 2019 | $402,680,000 | +6.4% | 2,817,521 | -1.7% | 0.36% | +2.6% |
| Q1 2019 | $378,499,000 | +40.8% | 2,866,986 | +8.6% | 0.35% | +21.1% |
| Q4 2018 | $268,854,000 | +10.3% | 2,640,226 | +17.7% | 0.29% | +10.3% |
| Q3 2018 | $243,761,000 | +13.3% | 2,243,338 | +2.9% | 0.26% | +4.4% |
| Q2 2018 | $215,057,000 | +7.3% | 2,179,337 | +6.5% | 0.25% | -2.7% |
| Q1 2018 | $200,352,000 | +6.5% | 2,046,291 | +1.0% | 0.26% | +6.2% |
| Q4 2017 | $188,109,000 | +9.0% | 2,026,595 | +0.7% | 0.24% | -0.4% |
| Q3 2017 | $172,571,000 | +6.8% | 2,011,781 | +5.1% | 0.24% | +3.0% |
| Q2 2017 | $161,572,000 | +0.3% | 1,914,584 | +1.6% | 0.24% | -4.8% |
| Q1 2017 | $161,151,000 | +17.0% | 1,884,150 | +6.5% | 0.25% | +10.7% |
| Q4 2016 | $137,689,000 | +0.8% | 1,768,871 | +1.5% | 0.22% | +0.4% |
| Q3 2016 | $136,576,000 | -9.2% | 1,742,258 | -11.4% | 0.22% | -13.5% |
| Q2 2016 | $150,476,000 | -18.4% | 1,965,734 | +1.1% | 0.26% | -19.8% |
| Q1 2016 | $184,484,000 | +4.0% | 1,944,800 | +2.3% | 0.32% | +1.9% |
| Q4 2015 | $177,383,000 | +16.5% | 1,900,188 | +6.3% | 0.32% | +7.5% |
| Q3 2015 | $152,321,000 | +1.9% | 1,787,593 | +2.4% | 0.30% | +9.7% |
| Q2 2015 | $149,458,000 | +1.1% | 1,746,208 | +0.3% | 0.27% | +0.7% |
| Q1 2015 | $147,847,000 | +11.2% | 1,741,424 | +12.9% | 0.27% | +3.5% |
| Q4 2014 | $132,976,000 | +9.5% | 1,541,927 | -3.5% | 0.26% | +6.2% |
| Q3 2014 | $121,425,000 | -5.9% | 1,598,117 | -2.5% | 0.24% | -8.3% |
| Q2 2014 | $128,994,000 | +12.0% | 1,638,439 | +6.7% | 0.26% | +9.5% |
| Q1 2014 | $115,156,000 | +0.2% | 1,535,419 | +2.7% | 0.24% | +1.3% |
| Q4 2013 | $114,901,000 | +6.5% | 1,495,713 | -3.9% | 0.24% | +2.6% |
| Q3 2013 | $107,855,000 | +8.9% | 1,555,901 | -0.6% | 0.23% | +3.6% |
| Q2 2013 | $99,055,000 | – | 1,564,856 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |